All lobbying filings

The McManus Group

The McManus Group filed a Q2 report for Roche Diagnostics on July 20, 2026, reporting $40,000 in lobbying income.

Lobbying for Roche Diagnostics · Diagnostic test manufacturing

As filed: THE MCMANUS GROUP for ROCHE DIAGNOSTICS.

All filings by The McManus Group · Everything Roche Diagnostics has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

Indiana

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Trade (domestic/foreign)

Issues related to global trade and tariffs.

Bills named in this filing 3

H.R. 5269
RESULTS Act
H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.